LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada
ConditionLung Neoplasms
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-130
SponsorAstraZeneca
About this trial
LUNG-ROLL is a retrospective cohort study that will describe the contemporary treatment patterns, prevalence and incidence, patient demographic and clinical characteristics, clinical outcomes, and healthcare resource use/costs for patients with lung cancer in Canada (specifically, Alberta and Ontario) using administrative data.
Eligibility criteria
Qualifiers
Patients with lung cancer between January 1, 2018 and end of the Selection Period.
Patient is 18 years of age or older on diagnosis date.
Patient has at least 12 months of health insurance coverage prior to the diagnosis date.
Disqualifiers
Diagnosed with any other cancer in the 5-year period prior to January 1, 2018.
Diagnosed with any other cancer concurrently (i.e., on the same date) as lung cancer diagnosis.
Invalid or incomplete records for key variables (e.g., missing year of diagnosis, missing cancer type).
Non-Ontario or non-Alberta resident on diagnosis date.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
60,000 Participants
are grouped into 2 trial groupsLocations
2Research SiteT2N1N4, CalgaryAlberta, Canada
Research SiteM5T3M6, TorontoOntario, Canada
Sponsors and collaborators
AstraZeneca
Lead sponsor
Source ClinicalTrials.gov